论文部分内容阅读
目的:研究胸腺肽α1对小肝癌术后红细胞免疫功能的影响。方法:将我科收治的40例小肝癌患者,随机分为两组(n=20),A组为单纯手术切除组,B组为手术切除联合胸腺肽α1治疗(术后日达仙1.6 mg皮下注射,每周2次,共52周)组。分别于术前(T1)、治后1月(T2)、治后3月(T3)、治后6月(T4)采静脉血、离心、收集红细胞,混入等体积Rowe液后液氮保存,采用酵母菌玫瑰花环法测定红细胞C3b受体花环率(RBC-C3bRR)、红细胞免疫复合物花环率(RBC-ICR)来检测红细胞免疫功能。术后采用超声、增强CT或MRI等措施随访6月,判断肝癌肝内复发情况。结果:术前两组红细胞免疫功能差异无统计学意义,术后RBC-ICR含量低于术前,但B组含量低于A组(P<0.05);术后RBC-C3bRR高于术前,但B组含量高于A组(P<0.05),表明B组红细胞免疫功能强于A组。术后6月A组6例肝癌肝内复发,B组2例肝癌肝内复发(P<0.05)。结论:胸腺肽α1正性调节红细胞免疫黏附补体致敏的癌细胞的功能,增强机体免疫灭活癌细胞的能力,从而降低小肝癌术后复发。
Objective: To study the effect of thymosin α1 on erythrocyte immune function after small hepatocellular carcinoma (HCC). Methods: Forty patients with small hepatocellular carcinoma who were treated in our department were randomly divided into two groups (n = 20). Group A was treated with surgical resection and group B with surgical removal combined with thymosin α1 Injection twice a week for a total of 52 weeks) group. Venous blood was harvested before operation (T1), at 1 month (T2), at 3 months after treatment (T3), at 6 months after treatment (T4), and collected erythrocytes. The RBC-C3bRR and the RBC-ICR of erythrocyte C3bRR were measured by yeast rosette method to detect erythrocyte immune function. Postoperative ultrasound, CT or MRI enhanced follow-up of 6 months to determine the recurrence of liver cancer. Results: There was no significant difference in RBC-ICR before operation between the two groups, but the content of RBC-ICR in group B was lower than that in group A (P <0.05) However, the content of B group was higher than that of A group (P <0.05), indicating that B group had stronger erythrocyte immune function than A group. Six patients in group A had intrahepatic recurrence of liver cancer in 6 months and two patients in group B had intrahepatic recurrence (P <0.05). Conclusion: Thymosin α1 positively regulates the function of erythrocyte immune adherent complement-sensitized cancer cells and enhances the ability of the body to inactivate cancer cells, thereby reducing the postoperative recurrence of small hepatocellular carcinoma.